Skip to main content

Table 2 Summary of single test and NGS performed in the cohort

From: Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape

 TotalTotalSingle test vs. NGS
Single testNGS testSingle testNGS
EGFRmutationn = 75 (%)N = 100 (%)n = 75 (%)
Mutant18 (24)23 (23)18 (24)20 (26.7)
 Exon 19 deletion91099
 p.L858R6664
 Exon 19 deletion and p.T790M2222
 p.L858R and p.T790M1111
 Uncommon mutations_4_4
Wild57 (76)77 (77)57 (76)55 (73.3)
 Concordant cases  73 (97.3)
 Discordant cases  2 (2.7)
ALK1 rearrangementn = 73 (%)n = 70 (%)n = 49 (%)
 Mutant5 (6.8)5 (7.1)5 (10.2)4 (8.2)
 Wild68 (93.2)65 (92.9)44 (89.8)45 (91.8)
 Concordant cases  48 (98)
 Discordant cases  1 (2)
ROS1 fusionn = 58 (%)n = 70 (%)n = 43 (%)
 Mutant0 (0)3 (4.3)0 (0)1 (2.3)
 Wild58 (58)67 (95.7)43 (100)42 (97.7)
 Concordant cases  42 (97.7)
 Discordant cases  1 (2.3)
c-METamplificationn = 62 (%)N = 100 (%)n = 62 (%)
 Mutant4 (6.5)2 (2)4 (6.5)0 (0)
 Wild58 (93.5)98 (98)58 (93.5)62 (100)
 Concordant cases  58 (93.5)
 Discordant cases  4 (6.5)
\